BiotechTube
Pacific Biosciences

Pacific Biosciences

PACB
United States

Pacific Biosciences is a pioneer in long-read sequencing, offering the HiFi (High Fidelity) sequencing platform known for its exceptional accuracy and ability to resolve complex genomic regions. The company's technology roadmap includes innovations in SMRT Cells, chemistry, and software to improve throughput and reduce costs, targeting scalable solutions for clinical research. With a focus on human genomics, cancer, infectious disease, and agrigenomics, PacBio aims to establish its HiFi sequencing as the gold standard for comprehensive genomic analysis.

pacb.com

PACB · Stock Price

USD 1.39+0.12 (+9.45%)
Market Cap: $422.8M

Historical price data

AI Company Overview

Pacific Biosciences is a pioneer in long-read sequencing, offering the HiFi (High Fidelity) sequencing platform known for its exceptional accuracy and ability to resolve complex genomic regions. The company's technology roadmap includes innovations in SMRT Cells, chemistry, and software to improve throughput and reduce costs, targeting scalable solutions for clinical research. With a focus on human genomics, cancer, infectious disease, and agrigenomics, PacBio aims to establish its HiFi sequencing as the gold standard for comprehensive genomic analysis.

Human GenomicsCancer GenomicsRare DiseaseInfectious DiseaseAgrigenomicsMicrobiome

Technology Platform

HiFi (High Fidelity) long-read sequencing based on Single Molecule, Real-Time (SMRT) technology, delivering reads up to 25 kb with 99.9% accuracy, enabling detection of all variant types, haplotype phasing, and direct epigenetic analysis.

Pipeline

91
91 drugs in pipeline18 in Phase 3
DrugIndicationStageWatch
pantoprazole + bismuth + metronidazole + tetracyclineHelicobacter InfectionApproved
EmtricitabineHepatitis B, ChronicApproved
A single oral 5 mg of duterium labeled methamphetamineMethamphetamine Metabolism, CYP2D6 GenotypeApproved
RamiprilEssential HypertensionApproved
Emtricitabine plus adefovir dipivoxilHepatitis B, ChronicApproved

Opportunities

Significant growth opportunity lies in the transition of HiFi sequencing from research to clinical applications, such as genetic testing, carrier screening, and rare disease diagnosis.
Expansion in agrigenomics and infectious disease surveillance also presents large, scalable markets.
The technology roadmap focused on cost reduction is key to unlocking these high-volume segments.

Risk Factors

Key risks include slower-than-expected market adoption versus entrenched short-read sequencing, intense competition from Illumina and Oxford Nanopore, potential delays in executing the technology roadmap to lower costs, and the financial challenge of reaching profitability while investing heavily in R&D and commercialization.

Competitive Landscape

PacBio's main competitors are Oxford Nanopore Technologies in long-read sequencing and Illumina in the broader NGS market. PacBio differentiates itself with the unique combination of long reads and very high (99.9%) accuracy (HiFi reads), which is critical for clinical applications. The recent addition of the Onso short-read system broadens its portfolio but places it in direct competition with Illumina's core business.